Cargando…

BCG in Bladder Cancer Immunotherapy

SIMPLE SUMMARY: Bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium bovis, is the most successful microbial immunotherapy of cancer in current use. Intravesical treatment with BCG is recommended for most patients with high-risk non-muscle invasive bladder cancer (NMIBC). In pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Song, Redelman-Sidi, Gil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264881/ https://www.ncbi.nlm.nih.gov/pubmed/35804844 http://dx.doi.org/10.3390/cancers14133073

Ejemplares similares

Could BCG be used to protect against COVID-19?
por: Redelman-Sidi, Gil
Publicado: (2020)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
por: Morelli, Tommaso, et al.
Publicado: (2022)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
por: Vilares, Ana T., et al.
Publicado: (2022)

Recognition and Treatment of BCG Failure in Bladder Cancer
por: Lightfoot, Andrew J., et al.
Publicado: (2011)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis
por: Chen, Xingfeng, et al.
Publicado: (2023)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature
por: Arsuffi, Stefania, et al.
Publicado: (2023)

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
por: Moreo, Eduardo, et al.
Publicado: (2022)

Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
por: KRAJEWSKI, WOJCIECH, et al.
Publicado: (2020)

Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer
por: Adamkiewicz, Mateusz, et al.
Publicado: (2021)

Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
por: Klinger, Danielle, et al.
Publicado: (2021)

BCG immunotherapy of rat sarcomata.
por: Baldwin, R. W., et al.
Publicado: (1973)

Immunotherapy for bladder cancer
por: Fuge, Oliver, et al.
Publicado: (2015)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model
por: Rentsch, Cyrill A., et al.
Publicado: (2013)

Immunotherapy With Bacillus Calmette-Guerin (BCG) in a 16-Year-Old With Urothelial Bladder Carcinoma
por: Martinez-Thomas, Jose M, et al.
Publicado: (2022)

Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors
por: Sun, Kai, et al.
Publicado: (2021)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

BCG Immunotherapy of a Rat Sarcoma
por: Baldwin, R. W., et al.
Publicado: (1973)

Reparameterized multiobjective control of BCG immunotherapy
por: Yue, Rongting, et al.
Publicado: (2023)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
por: Lim, Chun Jye, et al.
Publicado: (2021)

Treatment options in non-muscle-invasive bladder cancer after BCG failure
por: Brooks, Nathan A., et al.
Publicado: (2015)

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
por: Jallad, S, et al.
Publicado: (2014)

Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy
por: Rao, Manoj V., et al.
Publicado: (2013)

MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model
por: de Queiroz, Nina M. G. P., et al.
Publicado: (2021)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer
por: Ye, Kun, et al.
Publicado: (2022)

Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes
por: Krajewski, Wojciech, et al.
Publicado: (2020)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy
por: Lima, L, et al.
Publicado: (2013)

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
por: Krajewski, Wojciech, et al.
Publicado: (2020)

Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ou8vd3tlfml18ps7odijdtm71i